41.50
前日終値:
$42.44
開ける:
$42.54
24時間の取引高:
442.11K
Relative Volume:
0.70
時価総額:
$1.74B
収益:
$17.39M
当期純損益:
$-135.89M
株価収益率:
-8.944
EPS:
-4.64
ネットキャッシュフロー:
$-123.00M
1週間 パフォーマンス:
-4.05%
1か月 パフォーマンス:
+3.23%
6か月 パフォーマンス:
-14.92%
1年 パフォーマンス:
+46.95%
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
TARS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TARS
Tarsus Pharmaceuticals Inc
|
41.50 | 1.78B | 17.39M | -135.89M | -123.00M | -4.64 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-02 | 再開されました | Oppenheimer | Outperform |
2025-05-27 | 再開されました | H.C. Wainwright | Buy |
2023-11-20 | 開始されました | Goldman | Neutral |
2023-07-18 | 開始されました | William Blair | Outperform |
2023-05-18 | 開始されました | Guggenheim | Buy |
2022-08-01 | 開始されました | Barclays | Overweight |
2021-12-21 | 開始されました | H.C. Wainwright | Buy |
2021-11-23 | 開始されました | Oppenheimer | Outperform |
2020-11-10 | 開始されました | BofA Securities | Buy |
2020-11-10 | 開始されました | Jefferies | Buy |
2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
Bank of New York Mellon Corp Sells 915 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Should I buy Tarsus Pharmaceuticals Inc. stock before earningsHigh-yield investments - jammulinksnews.com
When is the best time to buy Tarsus Pharmaceuticals Inc. stockHigh-yield market plays - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability - Yahoo Finance
Tarsus Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - Autocar Professional
What analysts say about Tarsus Pharmaceuticals Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Arizona State Retirement System Purchases 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
What drives Tarsus Pharmaceuticals Inc. stock priceBreakthrough wealth creation - Autocar Professional
What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT) - The Globe and Mail
Tarsus Pharmaceuticals Shares Soar 4.47% on Strong Sales, Earnings - AInvest
Tarsus Pharmaceuticals: A Compelling Case for Investment in the Era of Anterior Segment Innovation - AInvest
Tarsus Pharmaceuticals: Making Big Strides (NASDAQ:TARS) - Seeking Alpha
William Blair Has Bearish Estimate for TARS Q2 Earnings - Defense World
What is William Blair’s Forecast for TARS FY2026 Earnings? - Defense World
How Tarsus Pharmaceuticals Inc. stock performs during market volatilityFree Investment Risk Control - Newser
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Return Potential - Newser
Bank of America Securities Reaffirms Buy Rating for Tarsus Pharmaceuticals at $68.00 - AInvest
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Amalgamated Bank - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Analysts - Defense World
(TARS) Investment Analysis - news.stocktradersdaily.com
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - simplywall.st
Janney Montgomery Scott LLC Sells 2,795 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc.(NasdaqGS:TARS) dropped from Russell Microcap Growth Index - MarketScreener
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Protalix BioTherapeutics (NYSE:PLX) Financial Comparison - Defense World
Tarsus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Tarsus Pharmaceuticals Becomes Oversold (TARS) - Nasdaq
When (TARS) Moves Investors should Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Rhumbline Advisers Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth - Investing.com Australia
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth By Investing.com - Investing.com India
Insider Sell: Aziz Mottiwala Sells 17,500 Shares of Tarsus Pharm - GuruFocus
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):